Millendo Therapeutics, Inc. announced the appointment of Thomas Hoover as Vice President, Commercial Strategy and Andrew G. Spencer, Ph.D. as Vice President, Preclinical Research and Development. Mr. Hoover will be responsible for development and implementation of the commercial strategy for MLE4901 and ATR-101 and joins Millendo from Sunovion Pharmaceuticals. Dr. Spencer will be responsible for the Company's preclinical operations including toxicology, pharmacology, and PK/ADME studies and joins Millendo from Ardelyx, Inc. Mr. Hoover most recently served as Vice President, New Products Planning and Corporate Development at Sunovion Pharmaceuticals, where he was responsible for product strategy, portfolio management and business development.

Dr. Spencer most recently served as Vice President, Pharmacology/DMPK at Ardelyx, Inc., where he made extensive contributions to the discovery and development of tenapanor and served as head of alliance management during partnerships with Sanofi and AstraZeneca.